Results 211 to 220 of about 21,169 (256)

Detecting androgen receptor (AR), AR variant 7 (AR-V7), prostate-specific membrane antigen (PSMA), and prostate-specific antigen (PSA) gene expression in CTCs and plasma exosome-derived cfRNA in patients with metastatic castration-resistant prostate cancer (mCRPC) by integrating the VTX-1 CTC isolation system with the QIAGEN AdnaTest. [PDF]

BMC Cancer
Liu HE, Vuppalapaty M, Hoerner CR, Bergstrom CP, Chiu M, Lemaire C, Che J, Kaur A, Dimmick A, Liu S, Metzner TJ, Araya M, Crouse S, Sprenger-Haussels M, Schlumpberger M, Leppert JT, Hauch S, Sollier E, Fan AC.   +18 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Prostate-specific membrane antigen (PSMA): Current benefits and future value

Seminars in Surgical Oncology, 2000
We will review the evolution, benefits, and limitations of PSMA testing in the past, as well as its current and future value. Prostate cancer has been the most frequently diagnosed cancer and the second leading cause of cancer death in men in the United States.
A A, Elgamal, E H, Holmes, S L, Su, W T, Tino, S J, Simmons, M, Peterson, T G, Greene, A L, Boynton, G P, Murphy   +8 more
openaire   +3 more sources

Prostate-Specific Membrane Antigen (PSMA) Avid Pancreatic Neuroendocrine Tumor

Clinical Nuclear Medicine, 2016
Ga-PSMA PET/CT is increasingly used to evaluate recurrent prostatic malignancy due to its high specificity. A 75-year-old man with a previous history of treated prostate cancer 3 years earlier presented with rising prostate-specific antigen (PSA) level and underwent Ga-PSMA PET/CT which demonstrated a PSMA-avid focus in the neck of the pancreas. Triple-
Shankar, Vamadevan, Deepa, Shetty, Ken, Le, Chuong, Bui, Robert, Mansberg, Han, Loh   +5 more
openaire   +2 more sources

The clinical role of prostate-specific membrane antigen (PSMA)

Urologic Oncology: Seminars and Original Investigations, 2002
Prostate cancer remains the most common cancer type in men in the United States. Efforts are increasing to evaluate and to discover diagnostic and therapeutic markers for prostate cancer patients. One of these, prostate-specific membrane antigen (PSMA), is a transmembrane protein highly expressed in all types of prostatic tissue, especially cancer. The
Sam S, Chang, Warren D W, Heston
openaire   +2 more sources

Comparative analysis of prostate‐specific membrane antigen (PSMA) versus a prostate‐specific membrane antigen‐like gene

The Prostate, 2003
AbstractBACKGROUNDCurrently prostate‐specific membrane antigen (PSMA) is showing promise both as an imaging and therapeutic target for occult prostate cancer metastases. First generation antibodies against PSMA are used for the FDA approved Prostascint™ monoclonal antibody scan and second generation antibodies are being developed for therapeutic ...
Denise S, O'Keefe, Dean J, Bacich, Warren D W, Heston   +2 more
openaire   +2 more sources

Comparative analysis of monoclonal antibodies against prostate-specific membrane antigen (PSMA).

The Prostate, 2014
Prostate-specific membrane antigen (PSMA), also known as glutamate carboxypeptidase II (GCPII), is generally recognized as a diagnostic and therapeutic cancer antigen and a molecular address for targeted imaging and drug delivery studies. Due to its significance in cancer research, numerous monoclonal antibodies (mAbs) against GCPII have been described
J. Tykvart, V. Navrátil, F. Sedlák, E. Corey, COLOMBATTI, Marco, FRACASSO, Giulio, F. Koukolík, C. Bařinka, P. Šácha, J. Konvalinka   +9 more
openaire   +2 more sources

Prostate-specific membrane antigen (PSMA) expression in breast cancer and its metastases

Clinical & Experimental Metastasis, 2017
The present study was undertaken to investigate the expression of prostate-specific membrane antigen (PSMA) in normal breast tissues, in cancerous breast tissues and in distant metastases from patients with breast cancer. Immunohistochemical analysis was performed to determine PSMA expression and angiogenic activity using anti-PSMA mAb and anti-CD31 ...
Mariz, Kasoha, Clara, Unger, Erich-Franz, Solomayer, Rainer M, Bohle, Claudia, Zaharia, Fadi, Khreich, Stefan, Wagenpfeil, Ingolf, Juhasz-Böss   +7 more
openaire   +2 more sources

Lutetium-177 prostate-specific membrane antigen (PSMA) theranostics: practical nuances and intricacies

Prostate Cancer and Prostatic Diseases, 2019
Theranostic principles utilize a molecular biomarker specific for a tumor target, initially for imaging to assess target expression and, if deemed suitable, for targeted therapy. This presents an exciting opportunity for a highly personalized treatment strategy in the era of precision medicine. Prostate-specific membrane antigen (PSMA) theranostics has
Amir Iravani, John Violet, Arun Azad, Michael S. Hofman   +3 more
openaire   +2 more sources

Pharmacological upregulation of prostate‐specific membrane antigen (PSMA) expression in prostate cancer cells

The Prostate, 2018
BackgroundProstate‐specific membrane antigen (PSMA)‐based imaging and therapy are increasingly used for prostate cancer management. However, limitations are a low PSMA expression in certain patients. Androgen receptor axis inhibition can induce PSMA expression in vitro.
Kranzbühler, Benedikt, Salemi, Souzan, Umbricht, Christoph A, Müller, Cristina, Burger, Irene A, Sulser, Tullio, Eberli, Daniel   +6 more
openaire   +3 more sources